Skip to content

Study · Systematic review · 2026

2 results

Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.

Yu H, Wang J, Yin M, Ji L, Guo S, Liu T, Wang R

Obesity (Silver Spring, Md.)1 Sept 2026

PMID42644866 (opens in a new tab)PMCIDPMC13511386 (opens in a new tab)DOI10.1002/oby.70267 (opens in a new tab)PepBankPUB-42644866
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of RCTs in acquired hypothalamic obesity, semaglutide demonstrated sustained weight loss.

    In plain wordsIn a review of trials in people with obesity caused by hypothalamic damage, semaglutide gave lasting weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight loss in acquired hypothalamic obesity
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide demonstrated sustained weight loss
    1 context sentence
    Summary · context
    Seven RCTs were included.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 02HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In a systematic review of RCTs in acquired hypothalamic obesity, adverse events across the included pharmacological interventions were mostly mild to moderate.

    In plain wordsIn a review of trials across several drugs for hypothalamic obesity, side effects were mostly mild to moderate.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse events across pharmacological interventions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Adverse events were mostly mild to moderate.
    1 context sentence
    Summary · context
    Seven RCTs were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.